Other papers submitted by: Dr Jacques LeLorier

open access to scientific and medical research

News:

Expressions of interest for Editor-in-Chief - the International Medical Case Reports Journal Read more

Back to User profile » Dr Jacques LeLorier

Paper published by Dr Jacques LeLorier:

Original Research

Noteworthy comment: Most economic evaluation models compare a new patented drug (NPRx) to a generic comparator. The objective of this study was to examine the impact on the ICER of the future introduction of lower cost generic versions of the a new patented drug (NPRx) within the model’s time horizon. ICER estimated within economic evaluations comparing NPRx to generic comparators which ignore the future introduction of lower cost generic versions of the NPRx within the model’s time horizon will tend to be overestimated. Inclusion of this parameter should be considered within future economic evaluations.

Highly-accessed

Bias within economic evaluations – the impact of considering the future entry of lower-cost generics on currently estimated incremental cost-effectiveness ratios of a new drug

Guertin JR, Mitchell D, Ali F, LeLorier J

ClinicoEconomics and Outcomes Research 2015, 7:497-503

Published Date: 6 October 2015